Samsung Biologics Honored for Sustainability at CDMO Leadership Awards 2026

In a remarkable display of commitment to sustainability, Samsung Biologics has been awarded the prestigious Sustainability Leadership Award at the 2026 CDMO Leadership Awards, held on March 26, 2026, in New York. This recognition, presented by Outsourced Pharma and Life Science Connect, celebrates companies that are making significant strides in sustainable practices throughout their operations and value chains. In addition to the Sustainability Leadership Award, Samsung Biologics was recognized as "Best in Class" for Cultural Fit in the 'Biologics—Large CDMOs' category, which reflects its dedication to building strong partnerships based on shared objectives.

The CDMO Leadership Awards are designed to recognize top performers in the development and manufacturing services field, based on client feedback regarding various factors such as facility management, innovative practices, technical expertise, and manufacturing capabilities. Samsung Biologics has shown consistent excellence in these areas, garnering favorable ratings from clients that highlight its reliable execution and commitment to maintaining high service quality.

John Rim, the President and CEO of Samsung Biologics, stated, "Sustainability is a core value at Samsung Biologics and guides how we pursue excellence throughout our business and partnerships. This recognition reflects the trust our clients and partners place in us, as well as the hard work put in by our teams, who endeavor to weave sustainable practices into every aspect of our operations. We will continue to collaborate closely with our partners to help them achieve their long-term goals and to provide high-quality, life-saving medications to patients globally."

In its ongoing commitment to sustainability, Samsung Biologics has recently achieved a Platinum rating from EcoVadis, an accolade given to leading companies for outstanding performance in sustainability. The organization has launched a product carbon footprint (PCF) measurement system that has been validated independently, ensuring transparent and consistent emissions assessment. Furthermore, Samsung Biologics is actively involved in the Sustainable Markets Initiative (SMI) Health Systems Task Force, working to enhance collaboration with global suppliers towards decarbonization and the development of resilient supply chains.

Founded as a leading contract development and manufacturing organization (CDMO), Samsung Biologics offers comprehensive services ranging from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across its Bio Campus I and II, along with an additional 60,000 liters expected from a facility acquisition in Rockville, Maryland upon deal closure at the end of Q1 2026, the company is strategically positioned to accelerate its capacity and innovation in manufacturing.

Additionally, Samsung Biologics has laid groundwork for expanding its manufacturing footprint with plans for Bio Campus III, aimed at supporting next-generation therapies and emerging modalities. It leverages advanced technologies and specialized expertise to enhance diverse offerings that include multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

By adopting the ExellenS™ framework throughout its manufacturing process, Samsung Biologics ensures standardized designs, unified processes, and advanced digitalization to maintain operational consistency and efficiency across its global manufacturing network, which spans Korea, the U.S., and Japan. Samsung Biologics America acts as a support hub for clients in the U.S. and Europe, while its Tokyo office caters to the Asia-Pacific region.

As part of its ongoing efforts to enhance operational and quality excellence, Samsung Biologics continues to invest in capabilities that foster flexibility and responsiveness, ensuring the prompt delivery of safe, high-quality biomedicines. The organization is dedicated to making sustainable business choices that benefit society and advance global health initiatives.

For more details about Samsung Biologics, please visit Samsung Biologics Website.